Table 1.
Demographic and medical characteristics of neurosarcoidosis patients and/or patients suffering from SFN symptoms (n=89)
| Characteristics | Number (%) or median (25th-75th percentile) or mean±SD |
| Demographics | |
| Sex: male | 45 (51) |
| Age (yr) | 53.2±10.5 |
| Medical Variables | |
| Time since diagnosis (yr) | 6(2-12) |
| Age at diagnosis neurosarcoidosis (yr) | 44 (49.4) |
| SFN-related complaints (SFNSL >11) | 81 (91) |
| Medication use | 62 (70) |
| • prednisone | 32 (36) |
| • azathioprine (Imuran) | 3 (3) |
| • methotrexate | 30 (34) |
| • infliximab (Remicade) | 12 (14) |
| • adalimumab (Humira) | 4 (5) |
| • cyclophosphamide | 0 (0) |
| • other medication | 14 (16) |
| Psychological variables | |
| FAS score | 32.1±8.3 |
| WHOQOL-BREF | |
| Physical Health | 10.5±2.7 |
| Psychological Health | 13.2± 2.7 |
| Social Relationships | 13.5±2.9 |
| Environment | 15.2±2.2 |
| KSQ | |
| General Health Status | 55±19.2 |
| Lung (N=60, %) | 60.9±23.8 |
| Skin (N=20) | 66.7±22.5 |
| Eyes (N=41) | 54.3±22.6 |
| Medication (N=62) | 65.7±26.7 |
SFN=small fiber neuropathy, SFNSL=small fiber neuropathy screening list, FAS = fatigue assessment scale,
WHOQOL-BREF=World Health Organization Quality of Life BREF, KSQ=King’s sarcoidosis questionnaire